Notes d’épisode
For our first episode of season three, I sat down with Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech, where he leads the development of innovative therapies for cancer and inflammatory diseases. A physician-scientist and serial entrepreneur, Dr. Hanna previously founded the first academic drug development center at Duke University and has authored over 50 peer-reviewed publications. Under his leadership, Lamassu is advancing two novel therapeutics—RABI-767, now in Phase II trial, and SA53, a first-in-class oncology compound currently in Phase I/II trial. He also oversees Lamassu…
Site web: buildingbiotechspodcast.com

